Prostate News and Research

RSS

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Younger patients unable to cope with pain and emotional issues of cancer

Younger adult cancer patients have the most difficulty coping with the pain and emotional issues of cancer, in spite of their potentially better survival odds, according to a University of Michigan Health System study.

10 Nov 2010

$Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer$

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

Men with history of fracture and comorbidities are at an increased risk of fracture after long-term use of androgen deprivation therapy, and initiating this therapy should be carefully considered in older men with localized prostate cancer.

9 Nov 2010

GTx third quarter net loss decreases to $8.6 million

GTx, Inc. today reported financial results for the third quarter of 2010. The net loss for the quarter ended September 30, 2010 was $8.6 million compared with a net loss of $12.8 million for the quarter ended September 30, 2009. For the nine months ended September 30, 2010, GTx reported net income of $22.8 million compared with a net loss of $35.4 million for the same period in 2009.

9 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

New approach to treat castration resistant prostate cancer

9 Nov 2010

Chemotherapy for breast cancer does more harm than good

A fundamental principle of medicine is: "first, do no harm." However, for doctors who treat breast cancer, this is easier said than done. Every year, almost 22,000 Canadian women are diagnosed with breast cancer - their treatment usually involves surgery to remove a tumour and then chemotherapy to reduce the risk of cancer returning.

9 Nov 2010

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.

9 Nov 2010

Soy-based drug could prevent prostate cancer metastasis

Northwestern Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body.

8 Nov 2010

CytRx reports $4.4 million net loss for third quarter 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2010, and provided a business update. The Company also announced the filing of a shelf registration statement with the Securities and Exchange Commission to replace its existing shelf registration, which expires in December 2010.

8 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

First Edition: November 8, 2010

Today's health policy headlines include more post-mortem reports about the health law's impact on the election.

8 Nov 2010

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.

8 Nov 2010

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts

News outlets offer a variety of stories about Medicare, including details of a new bidding process for medical equipment and the scheduled cut in physician reimbursement.

8 Nov 2010

NCRI launches first virtual biobank for prostate cancer research

The first virtual biobank dedicated to prostate cancer research has been launched today by the National Cancer Research Institute (NCRI). The UK Prostate Cancer Sample Collection Database will house details of around 10,000 biological samples taken from men in the UK with and without prostate cancer.

8 Nov 2010

Pervasis receives $920,000 in grants under QTDP program

Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years.

8 Nov 2010

Radiotherapy can benefit men with high risk prostate cancer: Research

Men treated with radiotherapy as well as hormone therapy for advanced prostate cancer were 43 per cent less likely to die from the disease, according to trial results presented at the NCRI Cancer Conference in Liverpool today (Monday).

8 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010